GB201707955D0 - Dual amylin and calcitonin receptor agonists for treating diseases and disorders - Google Patents

Dual amylin and calcitonin receptor agonists for treating diseases and disorders

Info

Publication number
GB201707955D0
GB201707955D0 GBGB1707955.9A GB201707955A GB201707955D0 GB 201707955 D0 GB201707955 D0 GB 201707955D0 GB 201707955 A GB201707955 A GB 201707955A GB 201707955 D0 GB201707955 D0 GB 201707955D0
Authority
GB
United Kingdom
Prior art keywords
disorders
receptor agonists
treating diseases
calcitonin receptor
dual amylin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1707955.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyBioscience AG
Original Assignee
KeyBioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG filed Critical KeyBioscience AG
Priority to GBGB1707955.9A priority Critical patent/GB201707955D0/en
Publication of GB201707955D0 publication Critical patent/GB201707955D0/en
Priority to PCT/EP2018/063202 priority patent/WO2018211111A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1707955.9A 2017-05-18 2017-05-18 Dual amylin and calcitonin receptor agonists for treating diseases and disorders Ceased GB201707955D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1707955.9A GB201707955D0 (en) 2017-05-18 2017-05-18 Dual amylin and calcitonin receptor agonists for treating diseases and disorders
PCT/EP2018/063202 WO2018211111A1 (en) 2017-05-18 2018-05-18 Dual amylin and calcitonin receptor agonists for treating diseases and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1707955.9A GB201707955D0 (en) 2017-05-18 2017-05-18 Dual amylin and calcitonin receptor agonists for treating diseases and disorders

Publications (1)

Publication Number Publication Date
GB201707955D0 true GB201707955D0 (en) 2017-07-05

Family

ID=59220532

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1707955.9A Ceased GB201707955D0 (en) 2017-05-18 2017-05-18 Dual amylin and calcitonin receptor agonists for treating diseases and disorders

Country Status (2)

Country Link
GB (1) GB201707955D0 (en)
WO (1) WO2018211111A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274158B2 (en) 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
HUP0001272A3 (en) 1997-04-16 2012-12-28 Unigene Lab Inc Direct expression of peptides into culture media
CN1329502A (en) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 Pharmaceutical compositions containing insulin
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (en) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド Solid oral dosage forms containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
PL1651249T3 (en) 2003-07-23 2013-04-30 Novartis Ag Use of calcitonin in osteoarthritis
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (en) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー Use of compounds containing thiol groups as exhaust pump inhibitors
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP5222727B2 (en) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (en) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Stable nanocapsule systems for the administration of active molecules
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AU2012332265B2 (en) 2011-11-02 2016-11-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
HUE037663T2 (en) 2013-11-14 2018-09-28 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders

Also Published As

Publication number Publication date
WO2018211111A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
IL279300A (en) Glp-1 receptor agonists and uses thereof
IL279224A (en) Glp-1 receptor agonists and uses thereof
IL258092A (en) Glucagon receptor agonists
HK1255452A1 (en) Improved apelin receptor (apj) agonists and uses thereof
IL269853A (en) Proteins for the treatment of epithelial barrier function disorders
PL3145530T3 (en) Trail receptor agonists for treatment of fibrotic diseases
IL253026A0 (en) Calcitonin analogues for treating diseases and disorders
IL265178A (en) Antibody for treating autoimmune diseases
GB201707955D0 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201704429D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201711838D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201704355D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201813677D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201817943D0 (en) Galanin-2 receptor agonists
GB201414706D0 (en) Calcitonin mimetics for treating diseases and disorders
ZA201700081B (en) Payment acomplishment via human initiated contact

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)